Completed Access to Information Requests

Follow:

  • RSS
  • Cite
About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 23 record(s)

Req # A-2023-006

I would like a complete copy of the following notes: Meeting with official language minority communities (OLMC) Date: June 9, 2023 Reference Number: E23-0808 Organization: Office of the Commissioner of Official Languages Sector: Policy and Communications Branch, To: Deputy Heads (including a person appointed to a position of equivalent rank) Action Required: For information, Information Document: modernization of the Official Languages Act Date: June 13, 2023 Reference Number: C22-2813 Organization: Office of the Commissioner of Official Languages Sector: Policy and Communications Branch To: Deputy Heads (including a person appointed to a position of equivalent rank) Action Required: For information NDS – Access to the Commissioner's reserve – April 2023 Date: May 1, 2023 Reference Number: C23-3106 Organization: Office of the Commissioner of Official Languages Sector: Corporate Management Branch To: Deputy Heads (including a person appointed to a position of equivalent rank) Action Required: For signature

Organization: Office of the Commissioner of Official Languages

32 page(s)
July 2023

Req # A-2023-007

I would like to obtain a complete copy of all briefing notes, regardless of the topic, prepared for the Commissioner of Official Languages or sent to him between April 1, 2023, and July 23, 2023.

Organization: Office of the Commissioner of Official Languages

174 page(s)
July 2023

Req # A-2023-008

I would like to obtain a complete copy of the briefing note entitled “Meeting with ***** - Air Canada” provided on July 19, 2023. Organization: Office of the Commissioner of Official Languages Sector: Compliance Assurance Branch To: Deputy Heads

Organization: Office of the Commissioner of Official Languages

4 page(s)
July 2023

Req # A-2023-011

I would like three things please. 1) General records and information concerning how the Commissioner determines whether to intervene in proceedings initiated under section 77 of the Official Languages Act 2) Records concerning how the Commissioner determines whether to initiate proceedings on behalf of a complainant following an investigation 3) A copy of briefing note C22-2813 (Information document: Modernizing the Official Languages Act)

Organization: Office of the Commissioner of Official Languages

144 page(s)
July 2023

Req # A-2022-05111

Electronic copies of the following documents. In all cases, cabinet confidences may be excluded and draft versions of documents. In all of the requests below, “draft guidelines” refers to the PMPRB Guidelines that were published for comment on October 6, 2022, or any prior drafts or versions of those 2022 Guidelines (for example, if a draft version was circulated to Health Canada for comment in September 2022, it would be part of the “draft guidelines” for the purpose of this request). • Emails or other communications from Health Canada commenting on the draft guidelines, and that were sent between July 1, 2022, and October 6, 2022. • Emails or other communications from the Board members or Board Chair commenting on the draft guidelines, and that were sent between July 1, 2022, and October 6, 2022. • Any training presentations, training manuals, or summaries of the new guidelines prepared for use by the Board Staff, Board, or other governmental departments prepared between July 1, 2022, and October 6, 2022. • Any documents with calculations of how much prices will decrease under the draft guidelines, or under alternative pricing rules, and that were prepared between January 1, 2022, and October 6, 2022 (note the change in date relative to other requests). • Any documents comparing prices or price reductions under the draft guidelines and the old PMPRB Compendium of Guidelines and Procedures. • Any documents, including legal memos, on the compliance of the draft guidelines with legal decisions about the PMPRB, including Alexion Pharmaceuticals Inc. v. Canada (Attorney General), 2021 FCA 157, Merck Canada c Canada, 2022 QCCA 240, and Innovative Medicines Canada v. Canada (Attorney General), 2020 FC 725. • Any documents which discuss how a medicine’s therapeutic class and comparator products will be established under the draft guidelines. • Any documents showing how the Board Staff arrived at the exact pricing tests discussed in paragraph 33-35 of the draft Guidelines. • Any documents which discuss how Board Staff will assess whether a price is excessive *after* an investigation has been opened. For context, the backgrounder which accompanied the draft guidelines suggested that staff will consider “the totality of the circumstances surrounding the price of the medicine, through the lens of the section 85 factors.

Organization: Patented Medicine Prices Review Board Canada

197 page(s)
July 2023

Req # A-2023-025211

With regard to the c. 2003 HDAP Report on New Patented Drug - Angiomax (http://www.pmprbcepmb.gc.ca/view.asp?ccid=583), I am looking for a copy of any supporting research, reports and calculations used to determine dosage regimens. I am specifically interested in how these quantities (in mL) were derived, the benchmark patient weight that was used (in kg) and the timeframe of the dosing.

Organization: Patented Medicine Prices Review Board Canada

18 page(s)
July 2023

Req # A-2023-025599

For FY 2015-2022 (inclusive), how many investigations into prescription pricing on the basis that the pricing exceeded the guidelines resulted in a public hearing? Of those that resulted in a public hearing, in how many was the pricing found to be excessive? Of those that were found to be excessive, how many resulted in orders to reduce the prescription price?

Organization: Patented Medicine Prices Review Board Canada

1 page(s)
July 2023

Req # A-2023-025896

For fiscal years 2015-2022 (inclusive), how many new patented medicines were reported to the board by Bayer, Inc.? From among those reports, how many included claims that a price exceeded the guidelines?

Organization: Patented Medicine Prices Review Board Canada

588 page(s)
July 2023

Req # A-2023-025600

For FY 2015-2022 (inclusive), how many Advance Certificate Rulings were issued by the board?

Organization: Patented Medicine Prices Review Board Canada

0 page(s)
July 2023

Nothing to report this month

Organization: Canada Economic Development for Quebec Regions

July 2023
Date modified: